Baseline prostate-specific antigen (PSA) levels in midlife predict aggressive prostate cancer in African-American men

Mark A. Preston1*, Travis Gerke2,3*, Sigrid V. Carlsson4,5, Lisa Signorello2,6, Daniel D. Sjoberg4, Kathryn L. Penney2, Adam S. Kibel3, Quoc-Dien Trinh1, Mark Steinwandel8, Andrew J. Vickers7, William Blot8, Hans Lilja4, Lorelei A. Mucci2,7**, Kathryn M. Wilson2,7**

1 Brigham and Women’s Hospital, Boston, MA; 2 Harvard T.H. Chan School of Public Health, Boston, MA; 3 Moffitt Cancer Center, Tampa, FL; 4 Memorial Sloan-Kettering Cancer Center, New York; 5 Institute of Clinical Sciences, Sahlgrenska Academy at University of Gothenburg, Sweden; 6 National Cancer Institute, Bethesda, MD; 7 Channing Division of Network Medicine, Brigham and Women’s Hospital/Harvard Medical School, Boston MA; 8 Vanderbilt University School of Medicine, Nashville, TN

* These authors contributed equally as first authors
** These authors contributed equally as senior authors

Abstract

**Background:** Baseline prostate specific antigen (PSA) levels measured in midlife predict future prostate cancer mortality among white men. There are minimal data on whether a baseline PSA in African-American men, who experience the highest incidence and mortality of this disease, predicts future aggressive prostate cancer.

**Methods:** We undertook a nested case-control study among African-American men age 40 to 64 years who gave prediagnostic blood at enrollment in the Southern Community Cohort Study between 2002-2009 and were followed a median of 9 years for cancer incidence and mortality through 2015. Baseline total and free PSA levels were available for 197 prostate cancer cases (55 aggressive cases, Gleason ≥4+3=7, AJCC Stage III or IV, or cancer-specific death) and 569 age-matched controls. Conditional logistic regression was used to estimate odds ratios (ORs) with 95% confidence intervals (CIs) for the association between baseline PSA levels and risk of total and aggressive prostate cancer.

**Results:** Median PSA among controls was 0.72, 0.80, 0.94, and 1.03 ng/mL for men aged 40 to 49, 50 to 54, 55 to 59, and 60 to 64 years, respectively. Relative risk of total prostate cancer was strongly associated with baseline PSA levels in midlife: ORs (95% CIs) comparing PSA levels in the >90th percentile vs. ≤median were 93.7 (22.5-390) at 40 to 54 years and 77.0 (24.9-238) at 55 to 64 years. Risk of aggressive prostate cancer was also strongly associated with baseline PSA levels in midlife: ORs (95% CIs) comparing PSA levels in the >90th percentile vs. ≤median were 80.8 (14.7 to infinity) at 40-54 years and 31.1 (5.64 to 172) at 55-64 years. 100% (22/22) of aggressive cases in men age <55 years occurred among those with a baseline PSA above the age-specific median.

**Conclusions:** PSA levels in midlife strongly predict aggressive prostate cancer in a cohort of African-American men subject to opportunistic screening. Risk-stratified screening based on mid-life PSA should be considered.

**Conflicts of Interest:** None.

**Funding Acknowledgements:** This work was supported by the Dana-Farber/Harvard Cancer Center Mazzone Awards Program to MAP, the Dana-Farber/Harvard Cancer Center SPORE in Prostate Cancer (P50-CA090381 to LAM), Prostate Cancer Foundation Young Investigator Awards to LAM and KMW, and an American Urological Association Urology Care Foundation Scholar Award (MAP). Additional funding support was provided from the National Cancer Institute [grant numbers number R33 CA127768-02, P50-CA92629]; Swedish Cancer Society [3455]; Fundacion Federico; the Sidney Kimmel Center for Prostate and Urologic Cancers; David H. Koch through the Prostate Cancer Foundation; Cancer Center Support Grant P30 CA008748 (PI: Craig B. Thompson).